Amble review

If you are taking less to spend less, Amble charges you for the drug you skip. "Same price, every dose" sits directly above its plan table, so a quarter dose costs what a full dose costs. Credit where it is due: that sentence is printed before you hand over anything, and the whole commitment ladder is public, which is rarer than it should be. It suits the opposite reader — someone starting low who expects to climb, and wants the bill to hold still. Three things will cost you if you misread them. The lowest figures on the homepage are not the monthly rate; the month-to-month rung is the highest one. Two plan tables on the same page disagree about what six months costs, so check which one you are buying from. And the cheapest headline the site advertises appears at no rung of the plan table at all.

Vs median

$4/mo above the $175 median across the 299 of 548 programs here that publish a plain monthly rate

Market

$59–$1,300/mo is the full published spread on this site

Structure

Same price at every dose

Consult

Included in the price

Dietitian

Not confirmed

Labs

Not required

Pricing

Flat at every dose

Amble does not publicly identify the pharmacy that fills its prescriptions. No bloodwork is required before you start. A clinician review is included in the price.

Amble is a direct-to-consumer telehealth brand selling compounded semaglutide and tirzepatide as a once-weekly injection, alongside NAD+, sermorelin, glutathione and lipotropic injections. It prescribes in all 50 states with restrictions, and requires a live video or audio visit in New Mexico, Kansas, West Virginia, Louisiana and Mississippi. Pricing is published openly on a plan table rather than held behind an intake, and the one-month rung is the only month-to-month option — every longer plan is a single upfront payment. No compounding pharmacy is named.

ONE PRICE AT EVERY DOSE. A patient deliberately holding a quarter dose pays the same $179 as one at the top of the range, and the difference is medicine bought and never used

• THE PLAN TABLE CONTRADICTS ITSELF. Two tables on the same page price the six-month rung at $145/mo and $135/mo, so what the commitment buys depends on which one you read
• The homepage advertises "Plans starting at $99 per month" and "Starting at $135 per month", neither of which is the month-to-month rate — that rung is $179
• The "From $179" headline is attached to NAD+, sermorelin, glutathione, Lipo-B and Lipo-C as well, so it is a floor for the whole catalog rather than a GLP-1 price
• Every page header claims "100% online FDA regulated pharmacies", while its own FAQ correctly explains that 503A pharmacies are licensed by state boards and only 503B outsourcing facilities are FDA-registered
• No compounding pharmacy is named anywhere on the site
• Whether a month here is four weeks or a calendar month of medication is not published
• Compounded GLP-1s are not FDA-approved, and intentional microdosing is off-label and unproven

Amble is one of 548 low-dose GLP-1 programs compared on this site, and 299 of them publish a monthly rate you can read before signing up. The full list puts every published price in one place, with the companies that pay us listed first — something we state there, on the page it applies to.

Intentional GLP-1 microdosing is off-label and unproven — no randomized trial has established that a sub-label dose does anything, and any dose belongs with a clinician who knows your history. If you are going to have that conversation, have it with real numbers.

• What the evidence actually shows
• What microdosing GLP-1 costs
• Low dose vs full dose
• What a flat price costs at a low dose
• The true annual cost of a plan